Innovation Pharmaceuticals Inc (IPIX)

[kris_kade]

I would appreciate if someone who is more knowledgable can respond.

I see from this article that Sunitinib alone has fairly strong efficacy and can significantly shrink tumors in RCC. Please
see:

http://www.news-medical.net/health/Renal-Cell-Carcinoma-Treatments.aspx

The recent PR from CTIX reflected a combo regimen with the same outcome (tumor shrinkage).

Research by BIDMC combined Kevetrin™ with sunitinib on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that “the Kevetrin/sunitinib combination is the first we’ve used in which actual tumor shrinkage is noted.”


How are the researchers and/or company attributing that Kevetrin has made a difference and that the observed shrinkage is not due to Sunitinib ? Is there a article to show that sunitinib is not effective in cell line 786 ?

Thanks